ECOLAB INC. Q3 FY2024 earnings call

• Strong volume growth, continued strong value pricing, and robust operating income margin expansion led to 19% growth in adjusted earnings. - Increased the midpoint of full-year earnings guidance range. - Organic sales grew 4% with volume growth at 2% due to business wins and innovation. - Gross margin improved to 43.5% with SG&A productivity continuing to improve. - Growth engines in clean tech, high tech, and biotech showing strength. - Innovation pipeline at record levels with nearly $1.5 billion invested. - One Ecolab growth initiative progressing well, focusing on unlocking $55 billion penetration opportunity. - Balance sheet in healthy position with options for organic and inorganic growth.

Ecolab's third quarter was marked by broad-based performance. Institutional and Specialty grew 7% in volume with operating income margins north of 20%. Pest Elimination had high single-digit organic growth and high margins. Global High Tech, including data center cooling and water for microelectronics, grew at strong double digits. Life Sciences remained ahead of the curve in a huge long-term growth opportunity. Organic sales grew 4%, with volume growth improving to 2% driven by business wins and innovation. Gross margin increased 220 basis points to 43.5%, and operating income grew 22%, with NOI margin expanding 260 basis points to 17.9%.

• Increased the midpoint of full-year earnings guidance range. - Expects adjusted diluted earnings per share growth of 12%-15% in 2025 and years to come. - Aims to reach 20% operating income margin over the next 3 years. - NOI margin expected to be around 16.5% for full year 2024, 50 basis points better than early commitment.

• DPC deflation tailwinds fading and inflation normalizing could impact margin expansion. - Economic uncertainties and supply chain impacts from events like hurricanes could affect performance. - Volatility in raw material costs and global market conditions may influence growth and pricing.

Q: Health care and life sciences organic sales and margin prospects?

A: Health care becoming smaller, focusing on profitability and instrument reprocessing; life sciences a booming business with expected growth and margins in 30% range.

Q: Hurricane impact on institutional/specialty?

A: No significant business impact due to resilient supply chain, 92% sales produced locally, human impact noted but business side unaffected.

Q: Market share gains pace and drivers?

A: Share gains from new business wins and wallet share gains, both at record levels indicating strong sales momentum.

Q: Oil pricing drop impact on pricing and growth?

A: Value pricing not solely dependent on oil, focus on total value delivered, and economic slowdown in some regions may affect growth but confident in future trajectory.

Q: Retention over last couple of years?

A: Retention rate close to 95%, stable despite extreme years, focus on total value delivered ensuring customers benefit, leading to strong volume, pricing, and momentum.